

# Financial Tear Sheet

## Primary IR Contact

Ed Bell  
T +1 206-272-4345  
invest@ctibiopharma.com  
(mailto:invest@ctibiopharma.com)

## Transfer Agent

### Computershare

Mail:  
Computershare Investor Services  
P.O. Box 43078  
Providence, RI 02940-3078

Overnight Delivery:  
Computershare Investor Services  
250 Royall Street  
Canton, MA 02021  
United States of America

T: 312-588-4187  
F: 312-601-4332  
www.Computershare.com  
(http://www.computershare.com)

## Corporate Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited.

## Stock Performance: CTIC (Nasdaq)

Exchange NASDAQ CM (US Dollar)

Price **\$2.76**

Change  
(%) ▼ 0.03 (1.08%)

Volume 37,391

52 Week Low \$2.70

Market Cap \$118,598,241

Rolling EPS -1.03

PE Ratio 0

Shares Outstanding 42,970,377

Data as of 11/17/17 4:00 p.m. ET



## Recent Headlines & Events

Nov 08, 2017 - 1:30 a.m.

CTI BioPharma to Present at the Jefferies  
2017 London Healthcare Conference  
([phoenix.zhtml?c=92775&p=irol-  
newsArticle&ID=2315241](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2315241))

There are currently no events scheduled.

Nov 06, 2017 - 4:03 p.m.

CTI BioPharma Reports Third Quarter 2017  
Financial Results  
([phoenix.zhtml?c=92775&p=irol-  
newsArticle&ID=2314662](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2314662))

Oct 30, 2017 - 1:30 a.m.

CTI BioPharma to Report Third Quarter  
2017 Financial Results on November 6,  
2017 ([phoenix.zhtml?c=92775&p=irol-  
newsArticle&ID=2312295](http://phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2312295))

## Ownership Summary

### Shareholders

	<b>Holders</b>	<b>Value (\$MM)</b>	<b>% O/S</b>	<b>Shares</b>
Institution	69	72.31	49.6	21,302,135
Mutual Fund	19	4.18	3.1	1,309,807
Insider *	7	10.63	5.7	2,451,417

*\*Insider values reflect direct beneficial ownership.*

### Top Holders

	<b>Shares Held</b>	<b>% O/S</b>	<b>Share Change</b>	<b>Filing Date</b>
BVF Partners L.P.	8,596,357	20.0	0	09/30/17
OrbiMed Advisors, LLC	5,000,000	11.6	0	09/30/17
Baxalta, Inc.	1,567,398	3.7	0	01/01/17
NB Public Equity Komplementar ApS	1,356,635	3.2	90,000	12/31/16
The Vanguard Group, Inc.	1,076,049	2.5	322,670	09/30/17
Stonepine Capital Management, LLC	993,000	2.3	-1,291,381	09/30/17
Renaissance Technologies LLC	411,149	1.0	274,404	09/30/17
BlackRock Institutional Trust Company, N.A.	399,162	0.9	18,755	09/30/17
Deutsche Asset Management Americas	205,099	0.5	204,809	09/30/17
Geode Capital Management, L.L.C.	194,685	0.5	81,003	09/30/17

*Data provided by Nasdaq. Minimum 15 minutes delayed.*